Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is a promising healthcare company with strong potential for growth due to its innovative, multi-cancer early detection blood test that has the ability to detect all types of cancer, providing a significant advantage over its competitors. The company has shown strong performance in their first quarter results, with revenue beating expectations and volume growing by 50% year-over-year. Despite the challenges and uncertainties of FDA approval and reimbursement, GRAIL has established a significant market presence, and is primed for broader institutional adoption and continued success in the rapidly growing multi-cancer early detection market.

Bears say

GRAIL is facing uncertainties and variability in their 22%-23% revenue growth guide due to factors such as uncertainty in digital health partner uptake and post-ASCO ordering trends, the newer and unproven nature of Hims & Hers and WHOOP, and variability from the sales force ramp. Additionally, there are risks to the medical and life science tools sector that could negatively impact GRAIL, such as reduction in research and development budgets and government funding, decreased purchasing from healthcare customers, increased regulatory hurdles, and dependence on volatile emerging markets. Overall, these factors could potentially hinder GRAIL's growth and profitability.

GRAIL Inc (GRAL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 8 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.